NCT03506802 - TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | Biotech Hunter

Timeline

Start Date

July 10, 2018

Primary Completion Date

June 25, 2019

Study Completion Date

June 25, 2019

Conditions

HLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Interventions

RADIATION

18F-FHBG

Given IV

BIOLOGICAL

Aldesleukin

Given SC

BIOLOGICAL

Cellular Therapy

LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV

PROCEDURE

Computed Tomography

Undergo PET/CT

BIOLOGICAL

Filgrastim

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

PROCEDURE

Leukapheresis

Undergo leukapheresis

DRUG

Melphalan

Given IV

DRUG

Plerixafor

Given SC

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles